MAAT INDEX

CLAIM #6330 · Amgen Inc (AMGN) · 2026Q1 earnings call · Apr 30, 2026 · due Dec 31, 2026

We expect share repurchases not to exceed $3 billion.

Peter Griffith · CFO

PENDING
graded after results covering Dec 31, 2026 are reported

How to check this claim

Look at: Total share repurchases (cash spent buying back common stock), full fiscal year 2026

It came true if: Full-year 2026 share repurchases <= $3.0 billion

Where: Cash flow statement (financing activities, treasury stock/repurchases line) in 10-K or Q4 2026 earnings release

In context

nclude any potential business development transactions that may occur throughout the remainder of the year. Let me highlight a few updates to our outlook for the remainder of the year. For the full year, we now expect other revenue to be in the range of $1.7 billion to $1.8 billion. We now anticipate non-GAAP OI&E to be in the range of $2.2 billion to $2.3 billion of expense in 2026. We now expect a non-GAAP tax rate in the range of 15% to 16.5%. And let me remind you of prior items that have not changed. We continue to expect the full-year non-GAAP operating margin as a percentage of product sales to be roughly 45% to 46%. This reflects our commitment to investing in the best innovation as we continue to rapidly advance the Meritide Phase III program and additional key late-stage assets. We expect share repurchases not to exceed $3 billion. Finally, in regard to our ongoing tax litigation, the tax court litigation covering tax years 2010 through 2015 remains ongoing, and while we expect a decision no earlier than the 2020, we remain confident in the case we presented at trial. We are currently under audit by the IRS for the 2016 to 2018 tax years. In April 2026, we received a draft Notice of Proposed Adjustment, or NOPA, from the IRS for 2016 to 2018, asserting significant adjustments primarily related to the allocation of profits between the United States and Puerto Rico. The approach taken by the IRS is similar in nature to our 2010–2015 dispute with the IRS currently pending in tax court. If sustained in full, the adjustments set forth in the draft NOPA could have a material impact on our financial statements. We disagree

Verify independently

SEC filings for AMGN · Claim quote is verbatim from the 2026Q1 earnings call.